Application of S100A8 as biomarker in preparation of diagnostic kit for anti-phospholipid syndrome
By using S100A8 as a biomarker, combined with ELISA kit to detect S100A8 levels in plasma, the diagnosis and prognosis difficulties of antiphospholipid syndrome were solved, good diagnostic sensitivity and specificity were achieved, and early prevention of obstetric antiphospholipid syndrome risk.
Patent Information
- Application Number
- CN202411321547.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art has not yet used S100A8 for the diagnosis and prognosis of antiphospholipid syndrome (APS), and there is no unified conclusion on the distribution of S100A8 in APS patients, resulting in difficulty in diagnosis and prognosis.
S100A8 was used as a biomarker to detect S100A8 levels in plasma by enzyme-linked immunosorbent assay (ELISA) kit for the diagnosis and prediction of obstetric antiphospholipid syndrome, and screen for positive antiphospholipid antibodies.
The test results show that S100A8 is significantly higher than disease control in APS patients, with good sensitivity and specificity, and can predict the risk of aPL-positive women who change to obstetric antiphospholipid syndrome. Early intervention can prevent pathological pregnancy.
Smart Images

Figure CN119064597A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of in vitro diagnosis, and in particular relates to the application of S100A8 as a biomarker in the preparation of a diagnostic kit for antiphospholipid syndrome. Background Art
[0002] Antiphospholipid syndrome (APS) is a syndrome characterized by recurrent arterial and venous thrombosis or habitual miscarriage, accompanied by persistent antiphospholipid antibodies (aPLs). New biomarkers are very important for the diagnosis and prognosis of antiphospholipid syndrome. S100A8 mainly exists in the form of calprotectin (S100A8 / A9). S100A8 is a calcium-zinc binding protein that plays an important role in regulating inflammatory processes and immune responses and can induce neutrophil chemotaxis and adhesion. At present, S100A8 has not been widely used in clinical practice to assist in the diagnosis and prognosis of APS. In the existing literature, there is no unified conclusion on the distribution of S100A8 in APS patients. Summary of the invention
[0003] The object of the present invention is to provide the use of S100A8 as a biomarker in the preparation of a diagnostic kit for antiphospholipid syndrome.
[0004] The present invention provides the use of S100A8 as a biomarker in the preparation of a diagnostic product for antiphospholipid syndrome, wherein the amino acid sequence of S100A8 is shown in SEQ ID NO.1.
[0005] Preferably, the biomarkers comprise blood biomarkers.
[0006] Preferably, the blood biomarkers include plasma biomarkers.
[0007] Preferably, the antiphospholipid syndrome includes obstetric antiphospholipid syndrome or thrombotic antiphospholipid syndrome.
[0008] The present invention also provides the use of S100A8 as a biomarker in the preparation of a product for predicting the risk of aPL-positive women developing obstetric antiphospholipid syndrome.
[0009] Preferably, the females include females of childbearing age.
[0010] Preferably, the biomarkers comprise blood biomarkers.
[0011] Preferably, the blood biomarkers include plasma biomarkers.
[0012] The present invention also provides the use of S100A8 as a biomarker in the preparation of a product for screening antiphospholipid antibody positivity.
[0013] Preferably, the biomarkers comprise blood biomarkers.
[0014] The present invention provides the use of S100A8 as a biomarker in the preparation of a diagnostic kit for antiphospholipid syndrome, wherein the amino acid sequence of S100A8 is shown in SEQ ID NO.1. The present invention detects the S100A8 level in the plasma of APS patients and healthy controls, performs statistical tests on the obtained data, and finds that the S100A8 level in the plasma of APS patients is significantly higher than that of disease controls and healthy controls. As an APS diagnostic indicator, S100A8 has good sensitivity and specificity. In addition, S100A8 positivity can predict the risk of aPL-positive women evolving into obstetric antiphospholipid syndrome. Detecting S100A8 in aPL-positive women of childbearing age and intervening early can prevent the occurrence of morbid pregnancy. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0016] Figure 1 This is a graph showing the difference in S100A8 concentration between healthy controls and patients with antiphospholipid antibody positive and antiphospholipid syndrome;
[0017] Figure 2 is the ROC curve (HC vs APS);
[0018] Figure 3 This is a graph comparing the S100A8 concentrations between aPL-positive patients and OAPS patients. DETAILED DESCRIPTION
[0019] The present invention provides the use of S100A8 as a biomarker in the preparation of a diagnostic kit for antiphospholipid syndrome (APS). In the present invention, the amino acid sequence of S100A8 is shown in SEQ ID NO.1, specifically:
[0020] MLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRK KGADVWFKELDINTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE.
[0021] In the present invention, the biomarker preferably includes a blood biomarker; the blood biomarker preferably includes a plasma biomarker. In the present invention, the antiphospholipid syndrome preferably includes obstetric antiphospholipid syndrome or thrombotic antiphospholipid syndrome.
[0022] In the present invention, S100A8 protein can be used for screening and diagnosis of APS.
[0023] In the specific implementation of the present invention, the kit used to detect the content of S100A8 is an enzyme-linked immunosorbent assay (ELISA) kit.
[0024] The present invention also provides the use of S100A8 as a biomarker in the preparation of a product for predicting the risk of aPL-positive women developing obstetric antiphospholipid syndrome.
[0025] Detection of S100A8 in aPL-positive women of childbearing age and early intervention can prevent the occurrence of morbid pregnancy.
[0026] In the present invention, the women preferably include women of childbearing age; the biomarkers preferably include blood biomarkers; and the blood biomarkers preferably include plasma biomarkers.
[0027] The present invention also provides the use of S100A8 as a biomarker in the preparation of a product for screening antiphospholipid antibody positivity.
[0028] In the present invention, the biomarkers preferably include blood biomarkers; the blood biomarkers preferably include plasma biomarkers.
[0029] In the specific implementation of the present invention, the kit used to detect S100A8 is a S100A8 ELISA kit, specifically, XueJet, CJT12029-96T.
[0030] To further illustrate the present invention, the application of S100A8 provided by the present invention as a biomarker in the preparation of a diagnostic kit for antiphospholipid syndrome is described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0031] Example 1
[0032] The S100A8 ELISA kit (Sci-Jet, CJT12029-96T) was used to detect the plasma S100A8 levels in 120 healthy controls, 78 aPL-positive patients, 40 thrombotic APS (TAPS) patients, and 74 obstetric APS (OAPS) patients. The basic information of the controls and APS patients is shown in Table 1.1.
[0033] Table 1.1 Basic information of APS patients and healthy controls used to measure plasma S100A8 concentrations
[0034] Clinical characteristics APS (n=114) Healthy controls (n=120) aPL positive (n=78) Age (mean ± standard deviation) 51.4±13.9 / 50.3±15.2 Gender (female / total number) 103 / 114(90.35%) 75 / 120(62.50%) 60 / 78(76.92%) TAPS 40 / 114(35.09%) / / OAPS 74 / 114(64.91%) / /
[0035] The experimental steps are as follows:
[0036] (1) Peripheral blood was collected using EDTA as an anticoagulant, centrifuged at 1000 g for 15 min, and the supernatant was collected;
[0037] (2) The ELISA kit was equilibrated at room temperature for 20 min;
[0038] (3) Add 50 μL of standard samples of different concentrations to each standard sample well;
[0039] (4) Add 50 μL of plasma to be tested into the sample well;
[0040] (5) Add 100 μL of HRP-labeled detection antibody to each well of the standard and sample wells, seal with a sealing film, and incubate at 37°C for 60 min;
[0041] (6) Discard the liquid, fill each well with washing solution (350 μL), let stand for 1 min, discard the washing solution, pat dry, and repeat this process 5 times;
[0042] (7) Add 50 μL of substrate A and B to each well and incubate at 37°C in the dark for 15 min;
[0043] (8) Add 50 μL of stop solution to each well and measure the OD value of each well at a wavelength of 450 nm within 15 min.
[0044] A standard curve was drawn with OD value as the horizontal axis and standard concentration as the vertical axis, and the S100 concentration of each sample was calculated accordingly.
[0045] The results showed that S100A8 was significantly increased in aPL-positive and APS patients ( Figure 1 ), S100A8 was used as a diagnostic indicator with good sensitivity and specificity (Youden index: 0.661; sensitivity: 0.877; specificity: 0.783).
[0046] Another 54 APS patients and 60 healthy controls were selected as the validation sample set (basic information is shown in Table 1.2), the S100A8 concentration of each sample was measured, and the ROC curve was drawn.
[0047] Table 1.2 Basic information of APS patients and healthy controls used as validation sample set
[0048] Clinical characteristics APS (n=54) Healthy controls (n=60) Age (mean ± standard deviation) 52.8±12.6 / Gender (female / total number) 47 / 54(87.04%) TAPS 15 / 54(27.78%) / OAPS 39 / 54(72.22%) /
[0049] The results showed that the diagnostic performance of S100A8 was still good (Youden index: 0.643; sensitivity: 0.889; specificity: 0.754, Figure 2 ). Comparison of S100A8 levels between aPL-positive patients and OAPS patients revealed that S100A8 levels in OAPS patients were significantly higher than those in aPL patients (p=0.041, Figure 3 Multivariate regression analysis corrected for anti-β2-glycoprotein I(+) showed that S100A8(+) could predict the development of obstetric antiphospholipid syndrome in aPL-positive women (p=0.048, Table 2).
[0050] Table 2 Results of binary logistic regression analysis of morbid pregnancy in patients with aPL(+)
[0051]
[0052]
[0053] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. Use of S100A8 as a biomarker in the preparation of a diagnostic product for antiphospholipid syndrome, wherein the amino acid sequence of S100A8 is shown in SEQ ID NO.
1.
2. The use according to claim 1, characterized in that: The biomarkers include blood biomarkers.
3. The use according to claim 1, characterized in that: The blood biomarkers include plasma biomarkers.
4. The use according to claim 1, characterized in that: The antiphospholipid syndrome includes obstetric antiphospholipid syndrome or thrombotic antiphospholipid syndrome.
5. Application of S100A8 as a biomarker in the preparation of a product to predict the risk of aPL-positive women developing obstetric antiphospholipid syndrome.
6. The use according to claim 5, characterized in that: The women include women of childbearing age.
7. The use according to claim 5, characterized in that: The biomarkers include blood biomarkers.
8. The use according to claim 7, characterized in that: The blood biomarkers include plasma biomarkers.
9. Application of S100A8 as a biomarker in the preparation of products for screening antiphospholipid antibody positivity.
10. The use according to claim 9, characterized in that: The biomarkers include blood biomarkers.
Citation Information
Cited By
Application of human protocadherin 18 as biomarker in preparation of products for diagnosis, auxiliary diagnosis or progress prediction of anti-phospholipid syndrome
CN119667170A
Application of human protocadherin 18 as a biomarker in the preparation of products for diagnosis, auxiliary diagnosis or progression prediction of antiphospholipid syndrome
CN119667170B
Obstetrical anti-phospholipid syndrome risk prediction method and system
CN121790006A
